AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01635946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isavuconazole
Description: oral
Study NCT01635946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: oral
Study NCT02045134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Soluble corn flour not rich in anthocyanins
Study NCT02045134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-anthocyanin rich corn flour
Description: Soluble corn flour at high content in anthocyanins
Study NCT02593474 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Naltrexone
Description: Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
Study NCT04719026 — intervention group
Intervention type: OTHER
Intervention: Full-mouth periodontal examination using computerised Florida probe
Description: It is an observational study to investigate the prevalence of periodontitis in cases and controls.
Study NCT03035851 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT03035851 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stretch and Strength
Study NCT00515814 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retina implant is surgically placed into subretinal position
Description: Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation \& mobility.
Study NCT04053270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: 16mg subcutaneous implant
Study NCT04053270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Afamelanotide
Description: 16mg subcutaneous implant
Study NCT04053270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo subcutaneous implant
Study NCT04053270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous implant
Study NCT02191891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836845
Description: Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
Study NCT02191891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
Study NCT03781375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week
Study NCT03781375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week
Study NCT03781375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Etanerceot
Description: Administered by subcutaneous injection twice a week
Study NCT03781375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally or subcutaneously once a week at the same dose as prior to study entry
Study NCT03781375 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally or subcutaneously once a week at the same dose as prior to study entry
Study NCT01218841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil lipid emulsion
Description: 0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
Study NCT01218841 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MCT/LCT
Description: 0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
Study NCT03220334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Description: The experimental group was treated with PRP for artificial gastric ulcer after ESD.
Study NCT03220334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group was treated with normal saline for artificial gastric ulcer after ESD.
Study NCT01303510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:~* 15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus~* 15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus~* 15 µg HA antigen of B/Florida/4/2006-like virus~Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1
Study NCT01485887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER
Description: Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
Study NCT01578941 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diary
Description: Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM.
Study NCT01578941 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diary
Description: Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM.
Study NCT04639869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenyramydol HCl 400 mg Film Tablet
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
Study NCT04639869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenyramydol HCl 400 mg Film Tablet
Description: Phenyramydol HCL 400 mg Film Tablet contains 400 mg phenyramydol manufactured by Pharmactive Ilac.San ve Tic A.S
Study NCT03542656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amyloid PET
Description: Dynamic PET acquisition for 60 minutes will be acquired after injection of 10 mCi 11C-PiB (39 frames: 8 x 15 seconds, 4 x 60 seconds, 27 x120 seconds).
Study NCT04639869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabral 400 mg Film Tablet
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
Study NCT04639869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabral 400 mg Film Tablet
Description: Cabral 400 mg Film Tablet 400 mg phenyramydol manufactured by Recordati Ilac SAn ve Tic A.S.
Study NCT03739866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenacapavir
Description: Administered subcutaneously in the abdomen
Study NCT03713580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Adding Venetoclax, a BCL-2 inhibitor, to standard high dose therapy prior to autologous stem cell transplant (ASCT).~Venetoclax is a novel, orally bioavailable, small-molecule B-cell lymphoma-2 (Bcl-2) family inhibitor.
Study NCT03655561 — intervention group
Intervention type: OTHER
Intervention: Non interventional research
Description: Participants are receiving the standard of care according to Nigerian Center for Disease Control (NCDC) Standard Operating Procedures for Lassa fever case management. This include the administration of intravenous ribavirin for Lassa confirmed cases as well as critically-ill Lassa suspected cases.
Study NCT02227082 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
Study NCT00974415 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2
Description: CO2 treatment delivered to randomized flank at each study visit
Study NCT00974415 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham treatment to other flank at each study visit
Study NCT03992274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced implementation of PrEP
Description: During Enhanced Implementation study sites will receive Implementation Support to plan and introduce PrEP by following the eight stages of the PrEP-adapted SIC. Implementation Support specifically will involve a centralized technical assistance system developed using US-based PrEP experience focused on addressing implementation issues identified through real-time analysis of client, clinic, and implementation data.
Study NCT03421730 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VR647 Inhalation Suspension (budesonide) 1 mg/2 mL delivered by the VR647 Inhalation System
Description: The VR647 Inhalation System consists of the VR647 Inhalation System 1 control unit, a VR647 nebulizer handset, a mouthpiece and VR647 Smart Cards designed specifically for this trial.
Study NCT03421730 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 1 mg/2 mL Pulmicort Respules delivered by a conventional jet nebulizer
Description: Commercial Pulmicort Respules (budesonide inhalation suspension 1 mg/2 mL) delivered by a conventional jet nebulizer operated to sputtering.
Study NCT02227082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olaparib
Description: The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
Study NCT00820859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TREA (Treatment Routes for Exploring Agitation)
Description: Individualized non-pharmacological treatment plan for agitation
Study NCT00820859 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Control Group
Description: A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Chemotherapy medication used to treat a number of types of cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navelbine
Description: Navelbine is an chemotherapy medication used to treat a number of types of cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome Injection
Description: Doxorubicin Hydrochloride Liposome Injection is an anti-cancer chemotherapy drug
Study NCT02732860 — intervention group
Intervention type: OTHER
Intervention: Molecular Profiling & In Vivo drug testing in pPDX and organoid cultures
Description: Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. In vitro organoid culture generation may also be performed if sufficient fresh tissue is available. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
Study NCT01942889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program
Description: Vit E, Vit C, Selenomethionine, Zinc gluconate
Study NCT01942889 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program
Description: Vit E, Vit C, Selenomethionine, Zinc gluconate
Study NCT00018356 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: exercise
Study NCT00018356 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: testosterone
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: G-CSF is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream.
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Colony-stimulating factor 3 (CSF 3) and, is a glycoprotein that stimulates the bone marrow to produce granulocytes and stem cells and release them into the bloodstream. May be used instead of G-CSF
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cancer medication that interferes with the growth and spread of cancer cells in the body
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine is a chemotherapy medication used to treat cancer. Vincristine works by stopping the cancer cells from separating into 2 new cells to stops the growth of the cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin is used to prevent harmful effects of methotrexate when methotrexate is used to treat certain types of cancer.
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate is a chemotherapy medication used to treat cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Doxorubicin Hydrochloride is a chemotherapy medication used to treat cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Medication used to treat acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), chronic myelogenous leukemia (CML), and non-Hodgkin's lymphoma
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide is a is a chemotherapy medication used to treat cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Carmustine is a chemotherapy medication used to treat cancer
Study NCT00632827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denileukin diftitox
Description: Denileukin diftitox is an antineoplastic agent, an engineered protein combining Interleukin-2 and Diphtheria toxin. Denileukin diftitox could bind to Interleukin-2 receptors and introduce the diphtheria toxin into cells that express those receptors, killing the cells
Study NCT00625196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone foroate/ vilanterol
Description: Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
Study NCT00625196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone foroate
Description: Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
Study NCT00625196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone foroate
Description: Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
Study NCT00625196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vilanterol
Description: Vilanterol will be available as dry powder inhaler.
Study NCT00625196 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vilanterol
Description: Vilanterol will be available as dry powder inhaler.
Study NCT00625196 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be supplied as dry powder inhaler.
Study NCT02516098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyoscine butylbromide
Study NCT02516098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyoscine butylbromide
Study NCT02686138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenapanor
Study NCT01463553 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS pleurodesis
Description: Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
Study NCT04608526 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fractal analysis
Description: Fractal dimension (FD) analysis, which can be measured in panoramic radiographs, is a technique that can be used to measure mandibular trabecular architecture and to determine early periodontal changes in alveolar bone. Fractal analysis method, which has become more and more popular in recent years; has features such as being easily accessible, not being affected by variables such as projection geometry and radiological density and providing objective data about trabecular structures. It can be measured in the patients' existing panoramic images and does not require extra imaging and material.
Study NCT03352830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RANAS Behavior Change Intervention
Description: The Risks, Attitudes, Norms, Abilities, and Self-Regulation (RANAS) Model is a health behavior change intervention, which has been successfully used in the area of water, sanitation, and hygiene. It draws from numerous health behavior theories, including the Theory of Planned Behavior, the Health Action Process, and the Health Belief Model. The model posits that the five factor blocks (risks, attitudes, norms, abilities, and self-regulation) that must be aligned toward the new behavior in order to influence change. A series of activities target each block accordingly.
Study NCT03352830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infrastructural Intervention - Direct Delivery
Description: Product demand is influenced, in part, by accessibility. Investigators are testing the degree to which this is true for liquefied petroleum gas (LPG) by establishing a direct delivery system for communities randomized to this treatment arm. Individuals in these communities are able to contact a 'delivery agent', contracted by the Kintampo Health Research Centre, who will: 1) retrieve their cylinder, 2) refill with LPG, and 3) return to the participant. The cost of delivery is free to the participant (paid by the study), but the participant is expected to fully pay for their own LPG.
Study NCT02006745 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Description: 24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
Study NCT02006745 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Telaprevir
Description: 12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA >25 but \<1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA >1000 iU/mL at week 4).
Study NCT00434330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
Study NCT00434330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
Study NCT02522585 — intervention group
Intervention type: OTHER
Intervention: Conservative management
Description: Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
Study NCT02464995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bronchial thermoplasty with the Alair System
Study NCT00434330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
Study NCT00434330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
Study NCT00434330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginesatide
Description: Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.